Key clinical point: Anthracyclines add toxicity with no evidence of improved survival in patients with HER2-positive breast cancer receiving a neoadjuvant chemotherapy regimen plus dual HER2 blockade with pertuzumab/trastuzumab.

Major finding: 3-year event-free survival estimates were 93.5% and 92.7% for the nonanthracycline regimen versus the anthracycline regimen (hazard ratio, 0.90; 95% confidence interval, 0.50-1.63).

Study details: Long-term follow-up results of TRAIN-2, a randomized phase 3 trial including 438 patients with previously untreated stage II-III HER2-positive breast cancer.

Disclosures: The TRAIN-2 study was sponsored by the Netherlands Cancer Institute and Roche. Ms. Van der Voort said she had no relationships to disclose.